Here are four points:
1. Previously, the ROI-C Cervical Cage was cleared only for use with autogenous bone graft.
2. LDR presented clinical literature review data to the FDA to investigate the risks and benefits associated with using allogenic bone graft with ROI-C.
3. The system is indicated for use in adult patients with degenerative disc disease of the cervical spine with accompanying radicular symptoms at one disc level from C2-T1.
4. LDR is a global medical device company focused on designing and commercializing proprietary surgical technologies for spinal treatments.
More articles on devices:
SeaSpine creates general counsel position: 5 things to know
IlluninOss Medical partners with Orthovactive
Amendia, Promimic enter into strategic venture: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
